ceruletide and Cystic-Fibrosis

Previously, we found that the University of North Carolina cystic fibrosis (UNC-CF) mouse had more severe experimental acute pancreatitis (AP) than wild-type (WT) mice characterized by exuberant pancreatic inflammation and impaired acinar apoptosis. Because exon 10 CFTR gene mutations exhibit different phenotypes in tissues such as the mouse lung, we tested the hypothesis that DeltaF508-CF mice also develop severe AP associated with an antiapoptotic acinar phenotype, which requires indirect effects of the extracellular milieu. We used cerulein hyperstimulation models of AP. More severe pancreatitis occurred in cerulein-injected DeltaF508-CF vs. WT mice based on histological severity (P < 0.01) and greater neutrophil sequestration [P < 0.0001; confirmed by myeloperoxidase activity (P < 0.005)]. In dispersed acini cerulein-evoked necrosis was greater in DeltaF508-CF acini compared with WT (P < 0.05) and in WT acini pretreated with CFTR(inh)-172 compared with vehicle (P < 0.05). Cerulein-injected DeltaF508-CF vs. WT mice had less apoptosis based on poly(ADP-ribose) polymerase (PARP) cleavage (P < 0.005), absent DNA laddering, and reduced terminal deoxynucleotidyltransferase biotin-dUTP nick end labeling (TUNEL) staining (P < 0.005). Unexpectedly, caspase-3 activation was greater in DeltaF508-CF vs. WT acini at baseline (P < 0.05) and during AP (P < 0.0001). Downstream, DeltaF508-CF pancreas overexpressed the X-linked inhibitor of apoptosis compared with WT (P < 0.005). In summary, the DeltaF508-CF mutation, similar to the UNC-CF "null" mutation, causes severe AP characterized by an exuberant inflammatory response and impaired acinar apoptosis. Enhanced acinar necrosis in DeltaF508-CF occurs independently of extracellular milieu and correlates with loss of CFTR-Cl conductance. Although both exon 10 models of CF inhibit acinar apoptosis execution, the DeltaF508-CF mouse differs by increasing apoptosis signaling. Impaired transduction of increased apoptosis signaling in DeltaF508-CF acini may be biologically relevant to the pathogenesis of AP associated with CFTR mutations.

Topics: Acute Disease; Animals; Apoptosis; Caspase 3; Ceruletide; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Enzyme Activation; Genotype; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mutation; Necrosis; Pancreas; Pancreatitis; Peroxidase; RNA, Messenger; Severity of Illness Index; Signal Transduction; X-Linked Inhibitor of Apoptosis Protein

Reserpine treatment resulted in altered enzyme secretion from rat pancreatic acini in response to carbamylcholine and secretin (1,2). This study was undertaken: (1) To evaluate if the alterations caused by reserpine can be prevented by EGF and/or cerulein treatments; (2) To determine the time-course of secretion recovery after reserpine treatment; and (3) To establish if EGF and/or cerulein treatments can accelerate such a recovery after the reserpine treatment. Male Sprague-Dawley rats (250-265 g) were used in these experiments. In experiment I, rats divided into three groups received either reserpine (R) or the reserpine vehicle for the controls (C) and the pair-fed controls (PF) for 7 d. During treatment, PF and R rats were given SC, twice a day, saline, EGF (10 micrograms/kg), cerulein (1 microgram/kg), or both at the same dose. C rats received saline in gelatin. In experiment II, rats were treated for 7 d with reserpine or the vehicle as described in experiment I, were allowed a 30-d recovery period and then were killed. In experiment III, C, PF, and R rats were treated for 7 d as described in experiment I; on the 8th d and for the next 6 d, reserpine rats received saline (reserpine-saline), cerulein, EGF, or both cerulein +EGF at the same dose as indicated in experiment I. C and PF rats received saline in gelatin. After sacrifice, acini were prepared, and amylase dose-response curves to carbamylcholine (Cch) and secretin were established. EGF, cerulein, or their combination given to R rats did not improve the desensitized secretory response to Cch.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Amylases; Animals; Carbachol; Ceruletide; Cystic Fibrosis; Disease Models, Animal; Epidermal Growth Factor; Male; Pancreas; Rats; Rats, Sprague-Dawley; Reserpine; Secretin

Chronic reserpine treatment of animals, an experimental model for cystic fibrosis (CF), results in generalized exocrinopathy, impaired secretion, and decreased pancreatic content of amylase. However, the mechanisms of altered acinar pancreatic function in both CF patients and reserpine-treated rats are still unknown. The present study was designed to investigate the secretory response of the rat pancreas after reserpine treatment. Rats were given reserpine (1 mg kg-1 day-1 ip) or vehicle, and killed 2, 4, or 7 days later. To distinguish between specific effects of reserpine and those related to secondary malnutrition caused by the drug, secretory response of a group of pair-fed animals to reserpine was also investigated. During reserpine treatment, body weight and food intake were significantly reduced from the 2nd day on. Amylase release from dispersed pancreatic acini, prepared from control pair-fed and from reserpine-treated rats were used to evaluate functional secretory capacity. After 7 days, both chronic reserpine and pair-feeding significantly decreased pancreatic amylase concentration to 75 and 50% of controls, respectively. Reserpine caused desensitization of the pancreatic acini secretory response to carbamylcholine, without altering maximal amylase release. Desensitization occurred gradually and reached a maximum after 7 days. Secretory responses to caerulein and to the phorbol ester 12.0-tetradecanoyl phorbol-13 acetate (TPA) were not altered. These findings indicate that desensitization of amylase release after reserpine was specific to this muscarinic agonist. It may result from increased endogenous acetylcholine release in the course of treatment.

Topics: Acetylcholine; Amylases; Animals; Body Weight; Carbachol; Ceruletide; Cystic Fibrosis; Disease Models, Animal; Eating; Male; Pancreas; Rats; Rats, Inbred Strains; Reserpine; Tetradecanoylphorbol Acetate; Time Factors

Pancreatic acini of control and reserpine-treated rats were incubated with the isotopic tracer 36Cl to compare Cl accumulation in the absence and presence of secretagogues and transport inhibitors. Two phases of Cl accumulation were ascertained in resting control cells: an initial rate (0-5 min) and a steady state level (10-30 min) of accumulation. Both phases were enhanced by acetylcholine (1 microM) and caerulein (10 nM), but not by 10 nM vasointestinal peptide or 10 microM forskolin. Exposure to 1 mM DIDS (4,4'-diisothiocyano-2,2'-stilbene disulfonic acid) inhibited both phases of Cl accumulation, whereas exposure to 1 mM amiloride had a delayed effect on the initial rate and reduced the steady state phase in both resting (unstimulated) or acetylcholine-stimulated cells. Furosemide (1 mM) had no effect on Cl accumulation when added to the cells just before tracer, but reduced it when added 10 min before. Neither the initial phase nor the steady state level of Cl accumulation were enhanced by acetylcholine in acini of reserpine-treated rats and the effect of DIDS on the initial phase was smaller than in control cells. Continued exposure to this inhibitor resulted, furthermore, in a significantly larger steady state Cl content. The inhibitory effects of amiloride and of a 10-min preincubation with furosemide were similar to those observed in control cells. These results suggest that Cl accumulates in rat pancreatic acini by way of DIDS-sensitive mechanisms that are activated by Ca2+-mediated, but not by cAMP-mediated, secretagogues. These mechanisms are altered in acini of reserpine-treated rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Acetylcholine; Amiloride; Animals; Biological Transport; Ceruletide; Chlorides; Colforsin; Cystic Fibrosis; Disease Models, Animal; Furosemide; Kinetics; Male; Pancreas; Rats; Rats, Inbred Strains; Reserpine; Vasoactive Intestinal Peptide

Topics: Bicarbonates; Ceruletide; Child; Child, Preschool; Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Female; Humans; Infant; Male; Pancreas; Pancreatic Function Tests; Secretin

Pancreatic juice was collected in vivo from control and reserpine-treated rats after stimulation with pilocarpine (0.2 mg/100 g body weight), dopamine (6--7 mg/100 g body weight), caerulein (90--100 pmole total dose) or with a combination of caerulein and secretin (6 u/100 g body weight) and the volume, amylase, bicarbonate and chloride outputs were compared. The results indicate that the secretory response to the three secretagogues was significantly reduced in the drug treated animals. Thus, the volumes of pancreatic juice were 57.0, 60.5, and 15.7% of those obtained in control rats after stimulation with, respectively, pilocarpine, dopamine, and caerulein. Amylase output was 63.8, 67.1, and 21.0% and bicarbonate output was 29.9, 46.8, and 6.2% of those observed in untreated rats after the same stimulants. Fluid secretion increased in the treated animals to 71.3% of that of controls when both caerulein and secretin were administered together and amylase output became greater than in control rats (151%). However, bicarbonate output was still 55.2% of that of controls with this combined stimulation. It is concluded that chronic reserpine administration impairs exocrine pancreatic secretion and that this effect involves both the acinar and ductal portions of the gland. This impairment involves the physiologic responses of these two segments of the glandular epithelium to both neural and hormonal stimulants. These findings suggest that the exocrine pancreatic disturbance in reserpine-treated rats may be similar to that observed in cystic fibrosis (CF), and because the treated rat has been proposed as a model for the human disease, they suggest the use of this model as a test system for the study of the pancreatic secretory abnormality in CF.

Topics: Amylases; Animals; Bicarbonates; Ceruletide; Chlorides; Cystic Fibrosis; Disease Models, Animal; Dopamine; Male; Pancreas; Pancreatic Juice; Pilocarpine; Rats; Reserpine; Secretory Rate